favipiravir for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 mild to moderate meta-analysis
Shinkai JapicCTI-205238		RCT	favipiravir	placebo	COVID-19 mild to moderate	some concern	107/49	safety concern	inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
2 studies excluded by filtering options (2 RCT / 0 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 mild to moderate meta-analysis